Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Top 10 medical stories of 2007
- 1TOYING WITH Children's Health: 2007 was a tough year for children's health. Millions of toys were taken from babies' hands after being found to contain lead paint. Thousands of dolls and play sets were recalled because their defective designs allowed detachable magnets to become swallowing and choking hazards. At least...
- Research articles 2008-01-06
- Glaxo SmithKline to close plant.(PUERTO RICO)
- Drug maker GlaxoSmithKline PLC said it will close its plant in Cidra, opened in 196, due to declining sales of drugs including the diabetes treatment Avandia, reports AP (Oct. 24, 2007). The company will transfer production of Avandia and the related drug Avandamet to other facilities...
- Research articles 2007-12-01
- Diabetes drug Avandia increases heart attack risk: report
- WASHINGTON AFP — An analysis of four clinical trials involving more than 14,000 patients found that diabetes medication Avandia rosiglitazone taken over a lengthy period of time increases the risk of heart attack by 42 percent, a report released Tuesday said. It marks one of the first studies to...
- Research articles 2007-09-11
- CR Report: New Oral Diabetes Medicines No More Effective, Safe than Lower- Cost, Older Drugs
- To: MEDICAL EDITORSContact: Susan Herold of Consumer Reports Best Buy Drugs, +1-202- 462-6262 WASHINGTON, July 16 /PRNewswire-USNewswire/ -- Newer prescription drugs to treat type 2 diabetes -- including much-promoted Avandia and Actos -- are no more effective or safe than older drugs and cost significantly more, according to the latest...
- Research articles 2007-07-16
- Congress lambastes FDA over risks related to diabetes drug
- WASHINGTON -- Safety concerns about a GlaxoSmithKline diabetes drug prompted some Democratic lawmakers on Wednesday to rebuke the Food and Drug Administration and call for increased regulation of the pharmaceutical industry. The controversy surrounding Glaxo's Avandia intensified when a medical expert told Congress that executives threatened to...
- Research articles 2007-06-07
- Controversy spikes over anti-diabetes drug Avandia
- WASHINGTON AFP — Controversy over diabetes drug Avandia heated up Wednesday as experts pointed to studies linking it to greater heart attack risk, while a GSK study claimed rosiglitazone is safe. The GlaxoSmithKline study published online Tuesday by the New England Journal of Medicine NEJM gave preliminary results of...
- Research articles 2007-06-06
- Avandia users seek answers
- Many people with type 2 diabetes are wondering whether to keep taking their medication now that a new report suggests Avandia, a pill widely used to help control blood sugar, can raise heart attack risk. As of Tuesday afternoon, the American Diabetes Association had fielded 70...
- Research articles 2007-05-23
- Rivals swoop in after report batters diabetes drug Avandia.(GlaxoSmithKline's drug Avandia increases heart-attack risk)
- Byline: RICH THOMASELLI Byline: RICH THOMASELLI
- Research articles 2007-05-28
- Personal-injury lawsuits against GlaxoSmithKline Plc to be
- Personal-injury lawsuits against GlaxoSmithKline Plc over its top- selling diabetes drug Avandia will be consolidated in a federal court in Philadelphia, a panel of judges concluded. The decision by the seven-member Judicial Panel of Multi-District Litigation came after lawyers argued last month in New York over the appropriate court for...
- Research articles 2007-10-30
- GlaxoSmithKline faces Chinese patent challenge.
- A group of Chinese generic drug manufacturers, believed to include Shanghai Sunve and Chongqing Taiji, are to dispute GlaxoSmithKline's patent for diabetes drug Avandia. A State Intellectual Property Office hearing is set for 18 August - analysts th A group of Chinese generic drug manufacturers,...
- Research articles 2004-08-06
- GLAXOSMITHKLINE (GSK).
- GlaxoSmithKline GSK unveiled strong third-quarter results, with EPS up 20 per cent on the year to 21.3p, boosted by disposal gains. Pharmaceutical sales at the UK's largest drug company rose by 10 per cent to GBP4.7bn, with growth strong in the Adv GlaxoSmithKline GSK unveiled strong...
- Research articles 2005-11-04
- Glaxo Gets an FDA Warning... With Teeth
- Well before Vytorin became a cause célèbre -- which is to say, about a year ago -- GlaxoSmithKline was the drugmaker getting slapped around by critics for downplaying or ignoring possible heart problems associated with its diabetes drug Avandia. That case, which led to new warnings on the drug's label...
- Blog posts 2008-04-12
Additional Resources
- Endocrinologists Welcome FDA Avandia Recommendation
- The American Association of Clinical Endocrinologists AACE, along with the rest of the medical community, has watched with concern the debate regarding usage of GlaxoSmithKline's rosiglitazone Avandia in diabetes and the question of whether it increases cardiovascular risk. AACE welcomes the recommendation of the Food and Drug Administration endocrine advisory...
- Research articles 2007-07-31
- Avandia liver reports won't affect labeling
- The FDA has decided not to pursue any labeling change or additional warnings for SmithKline Beecham's diabetes treatment Avandia rosiglitazone, despite reports of liver injury associated with the drug. In response to two cases of Avandia-associated liver injury reported in the 1/18 Annals of Internal Medicine, CDER Office of Drug...
- Research articles 2000-03-01
- Weitz & Luxenberg Responds to Study Casting Further Doubt on Avandia
- NEW YORK -- A further pall has been cast over Avandia, a drug for Type 2 diabetes. A new study has found that long-term use of the pharmaceutical increases heart attack risk by more than 40 percent and doubles the chance of heart failure. These findings are nearly identical to...
- Research articles 2007-10-01
- Teva Announces Settlement of Generic Avandia®, Avandamet®, and Avandaryl® Litigation with GlaxoSmithKline
- JERUSALEM -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the District Court case has been settled on terms that are confidential allowing Teva by license to enter the U.S. market with its generic versions of Avandia[R] Rosiglitazone Maleate, Avandamet[R] (Rosiglitazone Maleate/Metformin HCl) and Avandaryl[R] (Rosiglitazone Maleate/Glimepiride) oral tablets...
- Research articles 2007-09-27
- GlaxoSmithKline Responds to Press Release from Senate Committee on Finance About Avandia.
- M2 PRESSWIRE-22 May 2007-ExplorationInvestor: GlaxoSmithKline Responds to Press Release from Senate Committee on Finance About AvandiaC1994-2007 M2 COMMUNICATIONS LTD RDATE:22052007 Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small...
- Research articles 2007-05-22
- Diabetes drugs Actos and Avandia raise the risk of heart failure but do not increase the risk of heart-related death according to a team of researchers led by Richard Nesto of the Lahey Clinic Medical Center in Burlington Massachusetts, US
- Diabetes drugs Actos and Avandia raise the risk of heart failure but do not increase the risk of heart-related death according to a team of researchers led by Richard Nesto of the Lahey Clinic Medical Center in Burlington Massachusetts, US. The latest study found heart failure risks are greatest for...
- Research articles 2007-10-29
- Perlegen Seeking Genes Responsible for Actos® and Avandia® Side-Effects; Completed Collection of 3,000 DNA Samples
- MOUNTAIN VIEW, Calif. -- Perlegen Sciences announced today that it has completed the collection of more than 3,000 DNA samples from diabetic patients treated with Actos([R]) and Avandia([R]) in order to analyze the genetic variability associated with adverse events due to treatment with this class of medications. An estimated...
- Research articles 2007-06-15
- GlaxoSmithKline Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionKevin Wilson - Citigroup Yeah, thank you this Kevin Wilson from Citigroup in London. Three questions, if I may, JP. Firstly, in the U.S., the 2% decline in sales in the quarter. Could you break out the volume and any price element you saw, and perhaps also comment...
- Earnings calls 2007-07-25
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
